David Dai
Stock Analyst at UBS
(0.66)
# 3,719
Out of 4,711 analysts
18
Total ratings
25%
Success rate
-19.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $28.33 | -15.27% | 1 | Oct 24, 2024 | |
| NUVL Nuvalent | Initiates: Neutral | $100 | $84.22 | +18.74% | 1 | Oct 24, 2024 | |
| BPMC Blueprint Medicines | Initiates: Neutral | $88 | $90.14 | -2.37% | 1 | Oct 24, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $20 | $2.85 | +601.75% | 1 | Oct 24, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Buy | $35 | $19.83 | +76.50% | 1 | Oct 24, 2024 | |
| MRUS Merus | Initiates: Buy | $72 | $41.85 | +72.04% | 1 | Oct 24, 2024 | |
| KURA Kura Oncology | Initiates: Buy | $27 | $9.01 | +199.67% | 1 | Oct 24, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $69 | $56.83 | +21.41% | 1 | Oct 24, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | $50 | $25.61 | +95.24% | 1 | Oct 24, 2024 | |
| IOVA Iovance Biotherapeutics | Initiates: Buy | $17 | $7.38 | +130.35% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $11.60 | +158.62% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $28.67 | +109.28% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $13.08 | +182.87% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.91 | +2,976.92% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $14.60 | +173.97% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $3.18 | +1,157.86% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.37 | +2,009.70% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $35.64 | +45.90% | 1 | Mar 17, 2020 |
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $28.33
Upside: -15.27%
Nuvalent
Oct 24, 2024
Initiates: Neutral
Price Target: $100
Current: $84.22
Upside: +18.74%
Blueprint Medicines
Oct 24, 2024
Initiates: Neutral
Price Target: $88
Current: $90.14
Upside: -2.37%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $2.85
Upside: +601.75%
Nurix Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $35
Current: $19.83
Upside: +76.50%
Merus
Oct 24, 2024
Initiates: Buy
Price Target: $72
Current: $41.85
Upside: +72.04%
Kura Oncology
Oct 24, 2024
Initiates: Buy
Price Target: $27
Current: $9.01
Upside: +199.67%
Janux Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $56.83
Upside: +21.41%
IDEAYA Biosciences
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $25.61
Upside: +95.24%
Iovance Biotherapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $17
Current: $7.38
Upside: +130.35%
Oct 24, 2024
Initiates: Buy
Price Target: $30
Current: $11.60
Upside: +158.62%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $28.67
Upside: +109.28%
Oct 24, 2024
Initiates: Buy
Price Target: $37
Current: $13.08
Upside: +182.87%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.91
Upside: +2,976.92%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $14.60
Upside: +173.97%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $3.18
Upside: +1,157.86%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.37
Upside: +2,009.70%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $35.64
Upside: +45.90%